Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Becotatug vedotin plus pucotenlimab for EGFR-positive advanced penile squamous cell carcinoma
ChiCTR2600132258Phase 2Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of becotatug vedotin and pucotenlimab in penile squamous cell carcinoma (PSCC), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Objective Response Rate. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
becotatug vedotinpucotenlimab
03
Conditions
penile squamous cell carcinoma (PSCC)
Beyond the preview
Go deeper on ChiCTR2600132258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132258.